Results 31 to 40 of about 38,393 (221)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients

Medical Sciences, 2023
Type 2 diabetes mellitus (T2DM) is the world’s most common metabolic disease. The development of T2DM is mainly caused by a combination of two factors: the failure of insulin secretion by the pancreatic β-cells and the inability of insulin-sensitive ...
Elis Susilawati, Jutti Levita, Yasmiwar Susilawati, Sri Adi Sumiwi   +3 more
doaj   +1 more source

Treating hepatic steatosis and fibrosis by modulating mitochondrial pyruvate metabolism [PDF]

, 2019
A hepatic comorbidity of metabolic syndrome, known as nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence in conjunction with the pandemics of obesity and diabetes.
Finck, Brian N, McCommis, Kyle S
core   +2 more sources

GALNT2 as a novel modulator of adipogenesis and adipocyte insulin signaling [PDF]

, 2019
Background/objectives: A better understanding of adipose tissue biology is crucial to tackle insulin resistance and eventually coronary heart disease and diabetes, leading causes of morbidity and mortality worldwide.
Antonucci, A., De Bonis, Maria Caterina, Di Paola, R., Mangiacotti, D., Marucci, A., Scarale, M. G., Trischitta, V.   +6 more
core   +1 more source

PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy

Biomedicines, 2021
Over the last decades, the breast tumor microenvironment (TME) has been increasingly recognized as a key player in tumor development and progression and as a promising prognostic and therapeutic target for breast cancer patients.
Giuseppina Augimeri, Daniela Bonofiglio
doaj   +1 more source

Impact of Various Oral Hypoglycemic Agents on Hepatic Steatosis Reduction in MASLD and Type 2 Diabetes: Exploring the Bidirectional Relationship. A Narrative Review

Clinical Diabetology
OBJECTIVE: This review aims to explore the impact of various classes of oral hypoglycemic agents on hepatic steatosis reduction and liver functions in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D)
Emilia Kowalczyk, Iwona Gorczyca-Głowacka, Gerard Stupecki, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Przemysław Wolak   +5 more
doaj   +1 more source

Clinical effect of thiazolidinediones in subjects with disorders of carbohydrate metabolism in case of polymorphism rs1801282

Ожирение и метаболизм, 2020
BACKGROUND: The polymorphism rs1801282 (Pro12Ala) may be one of the reasons for the heterogeneous response of patients with carbohydrate metabolism disorders to thiazolidinedione therapy.
Tatyana V. Eremenko, Nikolay A. Matsievskiy, Natalya V. Vorokhobina, Irina Y. Matesius, Irina N. Abramashvili   +4 more
doaj   +1 more source

Comparison of the Effects of Metformin and Thiazolidinediones on Bone Metabolism: A Systematic Review and Meta-Analysis

Medicina, 2023
Objectives: Studies have shown that people with diabetes have a high risk of osteoporosis and fractures. The effect of diabetic medications on bone disease cannot be ignored.
Ru-Dong Chen, Cong-Wen Yang, Qing-Run Zhu, Yu Li, Hai-Feng Hu, Da-Chuan Wang, Shi-Jie Han   +6 more
doaj   +1 more source

The anti-atherogenic effects of thiazolidinediones [PDF]

, 2007
The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Thiazolidinediones significantly improve glycaemic control in diabetics by reduced
Honisett, Suzy, Komesaroff, Paul A, Stojanovska, Lily   +2 more
core  

Predicting Macrophage Spatial Localization from Single‐Cell Transcriptomes to Uncover Disease Mechanisms

Advanced Science, EarlyView.
This study presents a machine‐learning framework entitled MERLIN that infers the microanatomical localization of macrophages from single‐cell transcriptomic data in structured organs such as the kidney and brain. Applying this method to existing datasets from models of acute kidney injury and diabetic nephropathy uncovered spatially resolved insights ...
Junping Yin, Qi Mei, Hans‐Joachim Paust, Ning Song, Yu Zhao, Daniela Klaus, Melanie Eichler, Yijun Hua, Jie Qin, Weiting Cheng, Christina K. Weisheit, Veronika Lukacs‐Kornek, Isis Ludwig‐Portugall, Sibylle von Vietinghoff, Christian F. Krebs, Johanna Klughammer, Ulf Panzer, Christian Kurts, Jian Li   +18 more
wiley   +1 more source

Pharmacogenetics of Anti-Diabetes Drugs

Pharmaceuticals, 2010
A variety of treatment modalities exist for individuals with type 2 diabetes mellitus (T2D). In addition to dietary and physical activity interventions, T2D is also treated pharmacologically with nine major classes of approved drugs.
Johanna K. DiStefano, Richard M. Watanabe   +1 more
doaj   +1 more source